SkinBioTherapeutics PLC Notice of AGM and posting of Annual Report (7397V)
December 06 2023 - 2:00AM
UK Regulatory
TIDMSBTX
RNS Number : 7397V
SkinBioTherapeutics PLC
06 December 2023
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
Posting of Annual Report and AGM Notice
6 December 2023 - SkinBioTherapeutics plc, (AIM: SBTX, or the
"Company"), the life science business focused on skin health
confirms that the Notice of Annual General Meeting ("AGM"), form of
proxy and Annual Report and Accounts for the year ended 30 June
2023 have been posted to shareholders.
An electronic copy of the Annual Report and Accounts and the
Notice of AGM are also available on the Company's website -
www.skinbiotherapeutics.com/investor-relations .
The AGM will be held at 9:00am on Friday 29 December 2023 at The
Clarion Hotel, Witney Way, Boldon, NE35 9PE.
-Ends-
For more information please contact:
SkinBioTherapeutics plc Tel: +44 (0) 191 495 7325
Stuart J. Ashman, CEO
Manprit Randhawa, CFO
Cavendish Capital Markets Limited Tel: +44 (0) 20 7220 0500
(Nominated Adviser & Broker)
Giles Balleny, Dan Hodkinson
(Corporate Finance)
Charlie Combe (Broking)
Dale Bellis, Tamar Cranford-Smith (Sales)
Instinctif Partners (financial press) Tel: +44 (0) 20 7457 2020
Melanie Toyne-Sewell / Jack Kincade SkinBioTherapeutics@instinctif.com
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R) , is based upon discoveries made by Professor
Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of skin healthcare sectors,
the most advanced of which are cosmetic skincare and food
supplements to modulate the immune system by harnessing the
gut-skin axis. In each area SkinBioTherapeutics plans to exemplify
its technology through human studies. The Company's first product,
AxisBiotix-Ps(TM), a food supplement to address the symptoms of
mild to moderate psoriasis.
The Company listed on AIM in April 2017 and is based in
Newcastle, UK. For more information, visit :
www.skinbiotherapeutics.com and www.axisbiotix.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAUVVRROWUURAA
(END) Dow Jones Newswires
December 06, 2023 02:00 ET (07:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024